Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Maple tree, where did you get that information on toxicity? I don't believe your statement is accurate. Dr. Arad dosed 5,000 people with this compound in 2020, some up to very high levels according to her interview, and there were zero issues reported regarding dosing. There were no issues with toxicity reported. In fact, that's one of the advantages of Tollovir vs. other competing products because most of them start having increasing issues when the dosing is ramped up. Not the case with the Todos product.
I also think one should follow the recommended dosing regimen once one makes the decision to start taking the Tollovid. It's likely the 5 days was recommended to give one's immune system time to overcome the viral infection once replication was stopped by the 3CL protease inhibitor in Tollovid. But humans always try to tinker with what has been proven to work, thinking they'll increase or decrease the dosing or save money by not taking all of it. I don't know how someone can make a fair evaluation when they changed the conditions recommended by the manufacturer.
I believe I might have been infected with Covid months ago based on the number of people at my work location who contracted it (some dying). I never had any pronounced symptoms, but have had a few issues crop up since then that may or may not be related to long Covid. I've never tested positive either with PCR tests prior to several hospital visits, nor with rapid antigen tests. However, those are small snapshots in time over the longer 2-year period we've been dealing with the virus.
I decided to take the 5-day dose of maximum strength Tollovid. I took 3 capsules every 6 hours over the 5-day period. I never experienced any discomfort, pain, diarrhea or gas during this time. The only thing I did notice was a darkening of my stool, almost black in color. Before my last dose I popped open one of the capsules and the finely ground powder inside was black, so I attribute the stool color to the Tollovid based on the large dose I was taking. Within a couple of days of finishing the dosing, stool color returned to normal, even though I have continued on the normal Tollovid Daily regimen of 2 capsules per day, one morning and one evening.
It's hard to make any analysis of my conditions as a result of the dosing. I simply wanted to kill any virus that might be in organ tissue resulting from an earlier infection, after reading about how many people are showing up with massive amounts of the virus in organ tissue even though their lungs are now clear of virus.
I can report that a couple of long-term conditions have disappeared since taking Tollovid. I had a nagging long-term cough that initially was a side effect of taking a certain blood pressure medication. The medication changed years ago but the cough never went away. Tell me something to get me laughing and it would turn into a coughing fit. No longer the case after Tollovid. Also, had knee joint swelling and pain starting a few months ago, and that also is mostly gone after Tollovid. Your mileage may vary, but I believe in the product and will continue to take the daily product.
Gerald has likely grown tired of constant hand holding of some shareholders to keep them from freaking out and selling out. Every CEO has to deal with some shareholders who need constant reassurance they're not going to lose all of their investment. I recall seeing a tweet he made to someone a few months ago suggesting they sell their shares if were so unhappy with the way things were unfolding.
Perhaps that's good advice for some.
So what? That data lock will occur only after the all the data has been entered in the database and after that data has gone through extensive quality control checks to ensure accuracy of data entry.
From what we've been told regarding the trial, they added a number of new endpoints regarding new biomarkers that their continued research uncovered after the trial was initiated. They have world renowned experts in the field of trial design and analysis working on this. The only date provided was the data release. As far as I can remember, the only indicator of data lock was that it was coming soon, and the CEO has stated multiple times the 27th continues to be the release date.
Shareholders nerves starting to get wrecked a week out from data release is entirely self-imposed grief. We've got the best in the business running the trial and data validation and analysis. I refuse to let nervous shareholders shake my confidence in this study and this company because they are now starting to have doubts.
I know what I invested in. I know the level of expertise and commitment of the team assembled to administer and report on this trial. This is out of the CEO's control at this point and everyone should just chill the f*ck out and let it happen.
So what if the work being done pushes the date out a few days? I'm not expecting that but I understand the CEO is giving us the best estimate he can based on updates he's getting from his team. If someone is so insecure in their investment here that the date being pushed back another few days to ensure quality of data is their litmus test for continuing to own the stock, all I can say is I'll be waving to them on the sidelines on my way to the bank.
I'm sorry some are starting to lose sleep over their investment. I likely have far more invested here than anyone else posting (just an educated guess) and I'm NOT freaking out over the fact the data lock hasn't been announced yet. Try having a little faith these folks have reputable experts in their fields working on the data and analysis and stop second guessing everything because something didn't happen according to our self-imposed timetable. There are literally thousands of data points they've had to enter, check, and recheck again independently to satisfy the QC requirements. There's one opportunity to get this right, then comes data lock, then comes analysis and report-out. There is no possibility of fixing errors discovered later. None.
I'm not selling a single share, not one, if this gets pushed to February. By all indications Covid is going to be with us a very long time. I guarantee you everyone invested here will be demanding Gerald's head on a platter if they f*ck this up and have errors in the data which adversely impacts the trial outcome. Investors will be asking why we didn't take the time to get it right before locking the data. From what I've read on trial processes, the analysis will happen pretty quickly once data lock occurs. I'm not concerned one iota about data lock not occurring yet. As a quality control analyst, I understand the rigorous work involved and remain confident in my investment. I only wish others could be comfortable in their investment as well.
I'm done venting. My last piece of advice is if this investment is keeping your awake at night worrying it, you've invested too much. Time to lighten the share load until a comfort level is reached.
Link to the Latest MONI Newsletter
https://news.prod.monitalks.io/shitcoins/
I anticipate Moon Equity Holdings will soon announce the release of their new Cryptocurrency, a new coin the exemplifies the performance of their sinking turd stock. Move aside Bitcoin... here comes the pump-n-dump cryptocurrency for the most discriminating toilet bowl user.
Sales of the new MONI cryptocurrency will be initially rolled out in truckstop restrooms via a unique crypto vending machine created exclusively for worldwide distribution of the new coin. Further expansion to restrooms of strip clubs and adult book stores is planned by end of 2022.
Purchase of the new cryptocurrency via the new vending machines will provide the buyer with a free roll of Wall Street Blue Blood brand premium toilet paper. The first 100 rolls distributed will be personally signed by Alison herself, a rare treat that early investors in the new currency will surely cherish for many years.
Demand for the new cryptocurrency is expected to be high and drive the share price back above the 1 cent level.
Agree, buying more here as well. Just gotta get the funds moved. Been loading here for over a year. One more decent block to acquire before the data release.
Todos appears ready for emergence onto the world stage. Great time to be a shareholder. Best wishes to all shareholders during these exciting weeks ahead.
What price did Alison buy her shares?
Skin in the game? Alison? LMAO
I wonder if she was pals with Bernie Madoff before his downfall. Blue blood Wall Street types, you know, hanging out, discussing strategies for enticing suckers to invest. There's also zero evidence she is a MONI investor. Alison is no sucker.
Yes, I'm sure Alison and all the Power Girls are just loading up on MONI shares at this ridiculous price.
But if they wait another month, they'll be able to buy at 0.005. Gotta be careful, though... the sinking turd eventually gets flushed.
So where is the PROOF Alison has ANY skin in this game? Demands for evidence when it's convenient when challenging others, but nothing more than speculation and fodder where Alison and her blue-blood backers are concerned, right? Double standard, eh?
Someone show me anything where Alison has even $1 at stake here. Salary doesn't count. If she were being paid in MONI shares, it would count, but we have no proof of that other than hype and speculation.
Some believe she is entrenched here. I suggest she has nothing in this game and can resign and walk away at any time with zero lost financially. Nothing more than pride and reputation, which can be recovered in her next venture.
Shareholders have money at stake here that can be lost. What does Alison have invested? Show us the evidence.
I understand your concerns, but we also have to remember the context of our trial vs. Pfizer's and others.
1. Our trial was conducted in a hospitalized setting, not outpatient. Everyone (including FDA) understands it's much more difficult to get the patient size in a hospitalized trial. Hopefully they will take that into consideration.
2. Pfizer talks about significantly reduced hospitalization and deaths for high-risk patients, all treated within 3 days of symptoms in a pre-hospitalized setting. Todos is ACTUALLY treating high-risk patients IN a hospitalized setting with moderate to severe symptoms, some even close to death (as indicated in the observation trial). These are not patients at risk for severe symptoms as with Pfizer's claim. These are patients actually experiencing severe symptoms. I cannot reasonably believe the scientific community will dismiss our drug in favor of Pfizer's drug just because the study size is much smaller, when our results are actually saving lives.
3. Both Pfizer and Merck stopped their hospitalized trials because they were going badly, even as a blinded study. When one sees no improvements in any of the trial patients, there is no point in continuing the trial. Todos is not in that category. We tested where they didn't because as a small company that's our best bang for the buck and where we stand the greatest chance for success. When word gets out about our trial, demand for our drug will follow. FDA may have to re-evaluate their decision if they don't approve EUA for hospitalized patients. And as Gerald stated, doctors who see the effects for hospitalized patients may want to start administering Tollovir earlier to their patients before major symptoms develop.
4. We already know there will be a Phase 2/3 Tollovir trial to follow immediately after data release. Whether or not FDA accepts our data for EUA approval, Gerald has already stated he's been in touch with other countries where they are receptive to EUA approval pending results of the Tollovir trial. Revenues should ramp up nicely even if FDA sticks with the big boys at this point. When the Phase 2/3 trial concludes, they will have no choice but to approve Tollovir or face public backlash, as this info will be widely known by that point.
That dastardly TA, holding up the MONI share structure update. Don't they know they're preventing lift-off of the MOON Equity Holdings ROCKET?
Next News Update... MONI acquires multiple top-performing gold mines on the MOON. Investors go ALL IN on the exciting news.
"To Da MOON, Baby!!!" – Moon Equity Holdings Investor
The order for Europe was from the customer, T-Cell Protect. Should Todos wait for them to get EU approval before starting to fulfill the order?
In a recent tweet Gerald indicated that because they hadn't yet gotten EU approval, Todos was redirecting some of the supply chain originally intended for T-Cell Protect to the growing USA market for Tollovid.
I'm not seeing how that is as bad as some believe. One of our customers is having issues with their certification to sell our product, so we redirect our resources to where we ARE selling.
Perhaps T-Cell Protect should have waited until they had CE certification before inking the deal with Todos. Perhaps Todos should have turned them away until AFTER they had the CE certification. Perhaps Todos should continue to have their resources allocated to fulfilling this order that currently cannot be sold in Europe.
While not ignoring your concern, it sometimes seems investors will not be happy with any outcome. This is a small company with very limited resources, trying to reach the big stage with many things going on at once. Sometimes I think investors expect perfection and have little room for delays or things not working out perfectly.
If we all went to sleep and woke up in 3 months, I think we'd all be a lot happier than focusing on the day-to-day with this company. My opinion.
That's a valid point but I wasn't trying to be specific about individual posts. Some here clearly believe our CEO is being less than straightforward with investors. Some of that is based on their experiences with AMBS. There are non-shareholders posting here with intentions that clearly do not align with the goals of shareholders.
I have posted a question to GC on Twitter asking for an update on the mobile testing labs. I hope he replies but if not I won't automatically take that to mean he's dodging the question. He may not be able to report anything because of something developing which will be announced in the near future. Or perhaps the demand for testing labs isn't playing out as we hoped for. The Biden administration seems to be heavily focused on at-home testing with rapid test kits. Gerald has repeatedly posted on Twitter about that being the wrong approach, and I agree based on months of following his posts and his discussions with other medical professionals and researchers. The administration seems to have a knack for focusing on the wrong areas in their pandemic response, again and again. The CDC guidance is no longer trusted by much of the public.
That being said, I think there are more positive things happening here than things not working out as planned. I don't expect the CEO to be batting 1.000 and neither should anyone else. I would love to see the TolloTest being focused on harder than it is, but as GC has stated, there are limited personnel and limited funds to be able to address everything simultaneously. They devote time and resources to where it needs to be for the current business and regulatory environment. That may very well be the reason for no updates on the mobile labs. Resources devoted elsewhere for the time being. If we're getting more bang for the buck with in-lab testing than expected revenues from mobile labs, I have no problem with them delaying implementation of mobile testing for the moment.
As far as Gerald's time spent on Twitter posts engaging the medical and scientific community on all things Covid, I believe this is intentional because he is establishing himself as extremely knowledgeable on Covid and that will benefit us when data is released and Tollovir is in the spotlight on the world stage. Having that recognition and reputation cannot hurt. He doesn't gain that Covid knowledge and overall context of the pandemic by sitting idle. He has to engage with those on the front lines and make his case, and learn from their opinions and experience as well. Some see that as ignoring the company operation. I see it as a strategic part of what Todos is bringing to market. My opinion.
I didn't tweet Gerald. He had already made the post as we were posting about it here.
It is what it is. He can't give us the answer we're looking for until the deal is finalized. Sometimes sucks being an investor because we're in the dark most of the time. Continue to question but let's give them the time to get it done. Gerald has assured us it will be done prior to data release. If it's not, I become VERY concerned at that point.
What do investors want Gerald to say on this? Give a specific date for the inking of the final deal, when likely some of it is out of his control? Then when that date gets pushed we yell and scream again?
To clarify on your post... "every time a concern is posted someone comes out and tells the poster to sell."
A concern about something not going as planned or the CEO being overly promotional is one thing. But posting that one believes the CEO is untrustworthy and deceptive and lying to investors a much higher order of magnitude of concern, and that's why some recommend selling out and moving on.
Perhaps that's not the intent of the posts about concerns, but that's how they are being interpreted. Not trying to squash posting concerns, but words matter and interpretations are based on the words used.
You make a good point that Tollovir is not the only asset of this company. I ask myself what I will do if the Tollovir data is not as expected. I expect the share price will tank in the short term. However, given the already proven Videssa test that will hit the market in about one year, I will likely hold my shares but not buy more, and wait for that valuation to be realized in share price.
Always have a plan B. Investing is risky and hopefully no one is investing all of their savings in any one investment, or money they will need in the short term. I don't believe Todos management is lying to us, but many factors determine success and some are simply out of the company's control. For me, staying invested in Todos regardless of how the phase 2 data is perceived is a no brainer because of the products in their pipeline.
GLTA
No worries. I've been extremely busy with work, long hours and such. I hope you remain invested because I believe good things are coming our way, and those who lost money in AMBS certainly deserve to be rewarded here.
I see Gerald has some new Twitter posts, so I'll grab and post them shortly.
And for the record, it's Jorge Leon, not Jorge Leone. Many here are getting that wrong. It's a minor thing, but if this was not correct in press releases and presentations, investors would be ravaging the company for how it makes them look unprofessional to not get the little things right.
Mobile testing labs were not BS. They were ahead of their time. Testing demand declined dramatically when everyone assumed the pandemic was behind us.
Things have now changed, and I expect we will see re-emergence of the Todos mobile labs as demand skyrockets. Ask GC about these on Twitter and ask for an update. You seem to have a good relationship with him answering your questions on Twitter.
First of all, I'm not making excuses for Gerald. I have the same concern regarding closing the NLC deal. It is not out of the realm of possibility that Pfizer or some other big pharma might be trying to offer NLC and Dr. Arad a better deal than that offered by Todos. That's a possibility in any planned partnership. However, given the history of Todos with NLC at this point I make the conscious decision to not freak out and assume the worst. I believe the JV will be inked and solidly in place prior to the phase 2 data announcement on the 27th. Gerald has been questioned on this and has given a reasonable explanation for the delays. I have no reason to believe otherwise. Those who continue to view him as a liar and deceptive CEO shouldn't be invested here, regardless of your view on the science involved. My opinion.
Regarding the mobile testing labs, anyone who has followed the Covid debacle realizes there was a period where our government leaders and the mainstream media were declaring victory over Covid. Testing demand dropped dramatically and we saw this in our own testing revenues, which up to that point had been growing quite nicely. The mobile labs were created based on the anticipated need for additional testing, but the tested demand declined and they were never effectively put into service. Gerald has covered this topic on at least one interview or conference I have heard. He mentioned it again recently because now that testing demand is growing rapidly with Omicron out of control, we will likely start to see revenues from the mobile labs.
The client that stiffed the company has been questioned and answered by the CEO on Twitter, and has been posted here. I remember posting that series of responses. I know some despise his Twitter posts and don't read them, but that's their loss because there are nuggets of great info there. I have tried to pare down the reposts and just focus on posts that relate to sales, revenues, company operations and the like, and omit the posts related to Covid science and policy.
I have no issue with concerns from investors. However, most of these concerns have already been addressed by our CEO, yet some are still questioning what happened to those initiatives and assume the CEO is lying or over promising and never delivering.
I am confident in this company and continuing to buy shares. If I ever believe the CEO is deceiving investors, I'm out. Good advice for anyone.
Exciting times ahead for shareholders. For those not owning shares, they can observe the game from the sidelines and boo or cheer as they wish.
Agree with you, Alison has no skin in this game, it's all speculation and fodder.
Maybe one day she will, and maybe not, and investors are the fools in her game.
Getting a paycheck is not a vested interest defining "skin in the game." Nice try. Show us where Alison has even $1 at risk here.
ZERO Skin In The Game. Understood. Can you provide ANY proof, or just assumption/speculation?
One would think Alison would be loading up at these prices. I guess that answers the key question below.
How do you define "skin in the game"? Looks pretty clear you were referring to share ownership since you were comparing your "skin in the game", another investors, and Alisons. Unless you're somehow suggesting Alison has put personal funds into this company with no share ownership. Pretty dumb. Either way, where's the proof?
That's what I thought... there is none. Just speculation among investors. Asking for proof when it's convenient and taking the assumption as proof when it's not convenient. I see how this works.
Management compensation is not "skin in the game". Every CEO gets compensated. Investors want to see a CEO display confidence by buying shares in the company they manage. That's having skin in the game. Amazing to me how this definition changes from company to company, depending on whether one likes or dislikes the CEO.
Share Structure Update - 1/13/22
1,500,000 shares added since last update on 1/7/22.
https://www.otcmarkets.com/stock/TOMDF/security
If Todos paid anything, it was likely far less than some investors lost who previously invested too much in a penny stock with no revenues. Money well spent on the interview... not so much on betting the farm on a high risk rags to riches gamble.
Where's the proof Alison has any skin in this game? Any Form 4's? Or is this just an assumption on the part of shareholders?
I've been told that nothing matters but the regulatory filings. Press releases, Tweets, etc... none of that matters. Regulatory filings are the only thing anyone can hang their hat on. So where's the proof Alison owns a single share of MONI?
If I'm wrong on this I would appreciate some evidence. Thanks.
I transferred funds today in order to buy more Todos shares. We all know why... clearly it's going to be a multi-dollar stock. I realized that some time ago and tripled my earlier position in short order.
I really appreciate the great analysis and confidence in Todos... definitely helped spur my decision to buy more shares at this ridiculously undervalued price.